Skip to main content
. 2021 Dec 6;24:87–100. doi: 10.1016/j.omto.2021.12.002

Figure 1.

Figure 1

SNX5 is downregulated and associated with poor prognosis in ccRCC patients

(A) The expression of SNX5 in ccRCC tissues compared with adjacent normal tissues was analyzed using datasets from TCGA. (B) The expression of SNX5 in ccRCC tissues compared with adjacent normal tissues was analyzed using datasets from GSE15641. (C)The expression of SNX5 in ccRCC tissues compared with adjacent normal tissues was analyzed using datasets from GSE126964. (D) Representative IHC images showing the expression of SNX5 in ccRCC tissues and adjacent normal tissues. (E) SNX5 protein expression was downregulated in ccRCC tumor tissue using the CPTAC datasets. (F) The expression of SNX5 in ccRCC tissues was cored, and representative IHC images are shown. (G) Kaplan-Meier analysis of overall survival (OS) according to SNX5 expression in 150 ccRCC patients. (H) Patients with low expression levels of SNX5 had shorter overall survival than patients with high expression levels as determined using datasets from TCGA. (I and J) Kaplan-Meier was applied to analyze the association of SNX5 expression and recurrence rate in two HCC cohorts. (K and L) Univariate (K) and multivariate (L) Cox proportional hazards analyses were conducted to evaluate the HR of SNX5 for OS in patients with ccRCC. ∗p < 0.05; ∗∗p < 0.01.